三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
阿布昔替尼的应答率及应答时间优于度普利尤单抗
阿布昔替尼的应答率及应答时间优于度普利尤单抗
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:272KB
图片尺寸:1748*1316
同报告图片
/
4
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
所属报告:
泽璟制药-公司研究报告-新药步入商业化管线对外授权可期-241211(35页).pdf
打包全文图表
相关数据
度普利尤单抗(达必妥)全球销售额(2017-2025年)
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
收藏
行业数据
2026-05-28
原图定位
查看详情
吉卡昔替尼国内销售预测
| 指标 | 单位 | 2022 | 2023 | 2024 | 2025E | 2026E | 2027E | 2028E | 2029E | 2030E | 2031E | 2032E | 2033E | 2034E | 2035E | 2036E |
|------|------|------|------|------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| 总人口 | 百万人 | 1412 | 1410 | 1408 | 1405 | 1403 | 1400 | 1397 | 1394 | 1391 | 1389 | 1386 | 1383 | 1380 | 1378 | 1375 |
| 同比增速 | % |  | (0.15) | (0.10) | (0.20) | (0.20) | (0.20) | (0.20) | (0.20) | (0.20) | (0.20) | (0.20) | (0.20) | (0.20) | (0.20) | (0.20) |
| 骨髓纤维化（MF） |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 患病率（%） |  | 0.62% | 0.62% | 0.62% | 0.63% | 0.63% | 0.63% | 0.63% | 0.63% | 0.64% | 0.64% | 0.64% | 0.64% | 0.68% | 0.72% | 0.76% |
| 骨髓纤维化患者数量（万人） |  | 6.17 | 6.20 | 6.22 | 6.24 | 6.27 | 6.29 | 6.32 | 6.35 | 6.37 | 6.40 | 6.42 | 6.45 | 6.47 | 6.50 | 6.53 |
| yoy |  |  | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% |
| 中高危占比（%） |  | 70% | 70% | 70% | 70% | 70% | 70% | 70% | 70% | 70% | 70% | 70% | 70% | 70% | 70% | 70% |
| 中高危骨髓纤维化患者数量（万人） |  | 4.3 | 4.3 | 4.4 | 4.4 | 4.4 | 4.4 | 4.4 | 4.4 | 4.5 | 4.5 | 4.5 | 4.5 | 4.5 | 4.5 | 4.6 |
| 治疗率（%） |  | 70% | 71% | 72% | 73% | 74% | 75% | 76% | 77% | 78% | 79% | 80% | 81% | 82% | 83% | 84% |
| JAK抑制剂使用率（%） |  | 50% | 55% | 60% | 65% | 70% | 75% | 80% | 82% | 84% | 86% | 88% | 90% | 90% | 90% | 90% |
| 平均治疗时间（月） |  |  |  |  | 27.3 | 27.3 | 27.3 | 27.3 | 27.3 | 27.3 | 27.3 | 27.3 | 27.3 | 27.3 | 27.3 | 27.3 |
| 吉卡昔替尼市占率（%） |  |  |  |  | 3.0% | 15.0% | 20.0% | 25.0% | 30.0% | 35.0% | 40.0% | 45.0% | 50.0% | 50.0% | 48.0% | 46.0% |
| MF销售额（百万元） |  |  |  |  | 78.3 | 265.2 | 383.9 | 440.9 | 549.4 | 631.9 | 748.9 | 873.0 | 1004.4 | 1016.8 | 988.0 | 958.3 |
| 特应性皮炎（AD） |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 患病率（%） |  | 4.98% | 5.08% | 5.18% | 5.28% | 5.38% | 5.46% | 5.55% | 5.62% | 5.69% | 5.75% | 5.80% | 5.84% | 5.88% | 5.92% | 5.96% |
| 特应性皮炎患者数量（万人） |  | 7030 | 7160 | 7290 | 7420 | 7540 | 7650 | 7750 | 7840 | 7920 | 7990 | 8040 | 8080 | 8119 | 8158 | 8197 |
| 中重度占比（%） |  | 30% | 30% | 30% | 30% | 30% | 30% | 30% | 30% | 30% | 30% | 30% | 30% | 30% | 30% | 30% |
| 中重度特应性皮炎患者数量（万人） |  | 2109 | 2148 | 2187 | 2226 | 2262 | 2295 | 2325 | 2352 | 2376 | 2397 | 2412 | 2424 | 2436 | 2447 | 2459 |
| 治疗率（%） |  | 48% | 49% | 50% | 50% | 51% | 52% | 53% | 54% | 54% | 55% | 56% | 57% | 58% | 58% | 58% |
| 12岁以上患者占比（%） |  | 50% | 50% | 50% | 50% | 50% | 50% | 50% | 50% | 50% | 50% | 50% | 50% | 50% | 50% | 50% |
| JAK抑制剂使用率（%） |  | 5% | 8% | 12% | 16% | 19% | 21% | 23% | 25% | 23% | 21% | 19% | 17% | 15% | 13% | 11% |
| 平均治疗时间（月） |  |  |  |  | 2.0 | 2.5 | 3.0 | 3.0 | 3.0 | 3.0 | 3.0 | 3.0 | 3.0 | 3.0 | 4.0 | 5.0 |
| 吉卡昔替尼市占率（%） |  |  |  |  |  |  | 0.1% | 0.3% | 0.5% | 0.7% | 0.9% | 1.0% | 1.1% | 1.2% | 1.3% | 1.1% |
| AD销售额（百万元） |  |  |  |  |  |  | 47.0 | 135.0 | 251.1 | 315.1 | 378.6 | 388.6 | 389.8 | 382.4 | 480.9 | 432.5 |
| 斑秃（AA） |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 斑秃患病人数（万人） |  | 375.3 | 377.6 | 380.0 | 382.1 | 384.1 | 386.1 | 388.1 | 390.2 | 392.2 | 394.2 | 396.1 | 398.1 | 400.1 | 402.0 | 404.0 |
| 斑秃患病率（1/10万） |  | 0.27% | 0.27% | 0.27% | 0.27% | 0.27% | 0.28% | 0.28% | 0.28% | 0.28% | 0.28% | 0.28% | 0.29% | 0.29% | 0.29% | 0.29% |
| 中重度斑秃患病人数（万人） |  | 296.5 | 298.3 | 300.2 | 301.8 | 303.4 | 305.0 | 306.6 | 308.2 | 309.8 | 311.4 | 312.9 | 314.5 | 316.1 | 317.6 | 319.1 |
| 中重度斑秃患者占比（%） |  | 79% | 79% | 79% | 79% | 79% | 79% | 79% | 79% | 79% | 79% | 79% | 79% | 79% | 79% | 79% |
| 治疗率（%） |  | 90% | 90% | 90% | 90% | 90% | 90% | 90% | 90% | 90% | 90% | 90% | 90% | 90% | 90% | 90% |
| JAK抑制剂使用率（%） |  |  |  |  | 3% | 5% | 10% | 10% | 14% | 16% | 18% | 20% | 22% | 24% | 26% | 28% |
| 吉卡昔替尼份额（%） |  |  |  |  | 0.1% | 0.3% | 0.5% | 0.7% | 0.9% | 1.1% | 1.3% | 1.4% | 1.5% | 1.4% | 1.3% | 1.3% |
| 治疗时长（月） |  |  |  |  | 6.0 | 6.0 | 6.0 | 6.0 | 6.0 | 6.0 | 6.0 | 6.0 | 6.0 | 6.0 | 6.0 | 6.0 |
| AA销售额（百万元） |  |  |  |  | 6.1 | 30.9 | 88.0 | 173.3 | 243.2 | 336.0 | 443.5 | 528.0 | 620.2 | 630.1 | 633.2 | 633.2 |
| 强直性脊柱炎（AS） |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 患病率（%） |  | 0.280% | 0.282% | 0.28% | 0.285% | 0.286% | 0.287% | 0.288% | 0.289% | 0.290% | 0.291% | 0.292% | 0.293% | 0.294% | 0.295% | 0.296% |
| AS患者数量（万人） |  | 395 | 398 | 400 | 401 | 402 | 402 | 402 | 403 | 404 | 404 | 405 | 405 | 406 | 406 | 407 |
| NSAID或传统合成DMARDs无效比例（%） |  | 50% | 50% | 50% | 50% | 50% | 50% | 50% | 50% | 50% | 50% | 50% | 50% | 50% | 50% | 50% |
| NSAID或传统合成DMARDs无效患者数（万人） |  | 198 | 199 | 200 | 200 | 201 | 201 | 201 | 201 | 202 | 202 | 202 | 203 | 203 | 204 | 204 |
| 治疗率（%） |  | 48% | 49% | 50% | 50% | 51% | 52% | 53% | 54% | 54% | 55% | 56% | 57% | 58% | 58% | 59% |
| JAK抑制剂使用率（%） |  | 5% | 10% | 11% | 12% | 13% | 14% | 15% | 16% | 17% | 17% | 17% | 16% | 15% | 14% | 13% |
| 平均治疗时间（月） |  | 3.0 | 3.5 | 4.0 | 4.5 | 5.0 | 5.5 | 6.0 | 6.0 | 6.5 | 7.0 | 7.0 | 7.5 | 8.0 | 8.5 | 8.5 |
| 吉卡昔替尼份额（%） |  |  |  |  | 0.1% | 0.3% | 0.3% | 0.5% | 0.7% | 0.9% | 1.0% | 1.1% | 1.2% | 1.3% | 1.3% | 1.0% |
| AS销售额（百万元） |  |  |  |  | 8.5 | 26.1 | 51.6 | 74.5 | 112.0 | 136.1 | 143.1 | 159.3 | 174.4 | 174.4 | 134.4 |  |
| 终端销售 | 百万元 |  |  |  | 78.31 | 271.30 | 470.27 | 689.93 | 1025.53 | 1264.61 | 1575.51 | 1841.16 | 2065.37 | 2178.63 | 2273.54 | 2158.31 |
| VAT | % |  |  |  | 3.0 | 3.0 | 3.0 | 3.0 | 3.0 | 3.0 | 3.0 | 3.0 | 3.0 | 3.0 | 3.0 | 3.0 |
| 渠道费用 | % |  |  |  | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 |
| 营收 | 百万元 |  |  |  | 69 | 239 | 415 | 609 | 905 | 1116 | 1391 | 1625 | 1823 | 1923 | 2007 | 1905 |
| 成功率 | % | 100% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 经调整营收 | 百万元 |  |  |  | 69 | 239 | 415 | 609 | 905 | 1116 | 1391 | 1625 | 1823 | 1923 | 2007 | 1905 |

资料来源：注：蓝色为假设值，黑色为计算值 资料来源：泽璟制药公司公告，医药魔方，CDE，华泰研究预测
收藏
行业数据
2026-01-30
原图定位
查看详情
图24.贝福替尼临床数据对比同类药物
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
收藏
行业数据
2026-01-13
原图定位
查看详情
度普利尤单抗2024年销售额超140亿美元,持续快速放量中
fCDlubTku70gICB8IOmUgOWUrumine+8iOS6v+e+juWFg++8iSB8IOWinumAnyAgIHwKfC0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLXwKfCAyMDE3ICAgfCAyLjUgICAgICAgICAgICAgIHwgLSAgICAgIHwKfCAyMDE4ICAgfCA5LjMgICAgICAgICAgICAgIHwgMjcyJSAgIHwKfCAyMDE5ICAgfCAyMy4yICAgICAgICAgICAgIHwgMTUwJSAgIHwKfCAyMDIwICAgfCA0MC41ICAgICAgICAgICAgIHwgNzUlICAgIHwKfCAyMDIxICAgfCA2MS45ICAgICAgICAgICAgIHwgNTMlICAgIHwKfCAyMDIyICAgfCA4Ny4zICAgICAgICAgICAgIHwgNDElICAgIHwKfCAyMDIzICAgfCAxMTUuOSAgICAgICAgICAgIHwgMzMlICAgIHwKfCAyMDI0ICAgfCAxNDAuOSAgICAgICAgICAgIHwgMjIlICAgIHwKfCAyMDI1SDEgfCA4MC4yICAgICAgICAgICAgIHwgMjElICAgIHwKCui1hOaWmeadpea6kO+8mmluc2lnaHTvvIzotZvor7roj7LlhazlkYrvvIzlm73ph5Hor4HliLjnoJTnqbbmiYA=
收藏
行业数据
2025-12-26
原图定位
查看详情
截至2025年9月底,度普利尤单抗、司普奇拜单抗分别获批8项、3项适应症,且适应症持续拓展
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
收藏
行业数据
2025-12-26
原图定位
查看详情
度普利尤单抗全球范围销售收入
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
收藏
行业数据
2025-11-21
原图定位
查看详情
匹米替尼未来在TGCT适应症的收入预测及对和誉的销售分成
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
收藏
行业数据
2025-10-10
原图定位
查看详情
针对和誉的CSF-1R抑制剂匹米替尼,在国际多地区和新适应症以及里程碑付款的预测
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
收藏
行业数据
2025-10-10
原图定位
查看详情
全球首个FGFR4抑制剂联合IO在HCC的临床设计:依帕戈替尼联合阿替利珠单抗的临床二期试验方案
PHxiZWdpbl9vZl9ib3h8PnwgUGFydCB8IERvc2UgUmVnaW1lbiAgICAgICB8IFNhbXBsZSBTaXplIChOKSB8CnwtLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS18CnwgQSAgICB8IDE4MG1nIFFEICAgICAgICAgICB8IDYgICAgICAgICAgICAgICB8CnwgQSAgICB8IDMyMG1nIFFEICAgICAgICAgICB8IDYgICAgICAgICAgICAgICB8CnwgQSAgICB8IDE2MG1nIEJJRCAgICAgICAgICB8IDggICAgICAgICAgICAgICB8CnwgQSAgICB8IDIyMG1nIEJJRCAgICAgICAgICB8IDMzICAgICAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJrlhazlj7hQUFQ8fGVuZF9vZl9ib3h8Pg==
收藏
行业数据
2025-10-10
原图定位
查看详情
全球几款早于和誉依帕戈替尼进入临床阶段的FGFR4抑制剂,大部分都已经停止开发
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
收藏
行业数据
2025-10-10
原图定位
查看详情
匹米替尼在一期临床试验中对比另外两款CSR-1R抑制剂显示出最佳的安全性,且无任何肝脏相关不良反应
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
收藏
行业数据
2025-10-10
原图定位
查看详情
全球约30%的肝细胞癌患者存在异常的FGF19-FGFR4通路改变,依帕戈替尼(ABSK011)的独特设计MoA
fCDlnLDljLogICB8IOavj+W5tOaWsOWinueXheS+i+aVsCB8CnwtLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tfAp8IOWFqOeQgyAgIHwg57qmMzDkuIcgICAgICAgICB8Cnwg5Lit5Zu9ICAgfCDnuqYxNeS4hyAgICAgICAgIHwKCui1hOaWmeadpea6kO+8muWFrOWPuFBQVO+8jOS+neW4leaIiOabv+WwvOmAmui/h+mdtuWQkUZHRjE5IC0gRkdGUjQg6YCa6Lev5rK755aX6IKd55mM
收藏
行业数据
2025-10-10
原图定位
查看详情
针对肝癌目前1L/2L治疗方案的ORR较低,mPFS较短,依帕戈替尼(ABSK011)有望改变这一状况
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
收藏
行业数据
2025-10-10
原图定位
查看详情
和誉首个商业化创新药匹米替尼(ABSK021)将
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
收藏
行业数据
2025-10-10
原图定位
查看详情
吡咯替尼或在国内乳腺癌新辅助治疗领域扮演帕妥珠单抗角色
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
收藏
行业数据
2025-09-28
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
头对头临床试验表明,JAK抑制剂乌帕替尼和阿布昔替尼相比 IL-4R抑制剂度普利尤单抗具有一定的临床优势,表现为对患者头颈部、躯干、上下肢的皮损清除疗效优于度普利尤单抗,且起效显著快于度普利尤单抗。阿布昔替尼的血药浓度达峰速度为 1小时,而度普利尤单抗则需要 3-7 天,并且乌帕替尼和阿布昔替尼对瘙痒和皮损缓解的应答率均显著高于度普利尤单抗。对度普利尤单抗应答不佳的患者,阿布昔替尼也可展现出显著的皮损和瘙痒改善效果。
行业数据
原图定位
当前图表所属:
泽璟制药-公司研究报告-新药步入商业化管线对外授权可期-241211(35页).pdf
主要JAK抑制剂适应症批准和销售情况
自免药物中国市场规模(单位:十亿美元)
自免药物全球市场规模(单位:十亿美元)
公司历年研发费用情况(单位:亿元)
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》